This afternoon we watched Viking Therapeutics rise 6.0% to a price of $53.8 per share. The Mid-Cap Pharmaceutical company is now trading -52.54% below its average target price of $113.36. Analysts have set target prices ranging from $90.0 to $138.0 per share for Viking Therapeutics, and have given the stock an average rating of buy.
Viking Therapeutics has an elevated short interest of 15.5%. The stock's short ratio, or the number of days needed for all shorts to cover their positions, is 3.63. Only 6.0% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. 75.2% of Viking Therapeutics shares are held by institutional investors, which indicates a high level of confidence in the stock.
Institutions Invested in Viking Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | FMR, LLC | 15% | 16,347,292 | $879,484,297 |
| 2024-03-31 | Blackrock Inc. | 8% | 8,274,174 | $445,150,554 |
| 2024-03-31 | Vanguard Group Inc | 7% | 7,785,724 | $418,871,945 |
| 2024-03-31 | Avoro Capital Advisors LLC | 3% | 3,590,000 | $193,141,997 |
| 2024-03-31 | State Street Corporation | 3% | 3,326,567 | $178,969,302 |
| 2024-03-31 | Geode Capital Management, LLC | 2% | 2,326,779 | $125,180,708 |
| 2024-03-31 | Alliancebernstein L.P. | 1% | 1,560,878 | $83,975,235 |
| 2024-03-31 | Pictet Asset Management Holding SA | 1% | 1,378,036 | $74,138,335 |
| 2024-03-31 | Viking Global Investors, L.P. | 1% | 1,094,940 | $58,907,771 |
| 2024-03-31 | Voya Investment Management LLC | 1% | 1,068,597 | $57,490,517 |
For these reasons, we consider that the Viking Therapeutics is the subject of mixed market sentiment.
